Mazdutide

Mazdutide is the editorial inflection point for the China regulatory pathway in metabolic peptide therapeutics. On June 27, 2025, China's National Medical Products Administration approved mazdutide for chronic weight management in adults under the brand name Xinermei (信瑞利), making it the first dual GCG/GLP-1 receptor agonist approved for weight management in any major jurisdiction. On September 19, 2025, the NMPA approved a second indication for glycemic control in adults with type 2 diabetes. Neither indication has an active Western regulatory submission as of mid-2026, and Eli Lilly — which licensed Chinese rights to Innovent Biologics in 2019 while retaining ex-China rights — has positioned retatrutide rather than mazdutide as its flagship next-generation global candidate. The result is a regulatory configuration unusual in pharmacology: a chronically-dosed metabolic peptide with two Phase 3 indications approved in China and no near-term path to FDA or EMA review.

The Phase 3 obesity readout is GLORY-1, published in NEJM in May 2025 (Ji et al. 2025). The trial randomized 610 Chinese adults with BMI ≥28 kg/m² (or ≥24 kg/m² with at least one obesity-related comorbidity) to once-weekly mazdutide 4 mg, 6 mg, or placebo for 48 weeks. Mean weight change was −12.05% on 4 mg, −14.84% on 6 mg, and −0.47% on placebo. The proportion of participants reaching ≥5% weight reduction was 73.5%, 82.8%, and 11.5% across the three arms; ≥10% loss was reached by 55.2%, 67.9%, and 2.9%; ≥15% loss by 37.0%, 50.6%, and 2.1%. Among participants with baseline liver fat ≥10% — a substantial fraction of the enrolled population given the East Asian visceral-fat phenotype — relative liver fat reduction at week 48 reached −65.85% on 4 mg and −80.24% on 6 mg versus −5.27% on placebo. The hepatic-fat magnitude is the strongest signal in the program and one of the strongest in any incretin-class trial published to date, comparable to the retatrutide Phase 2a MASLD result. The adverse-event profile was the expected GI signature, dominated by nausea, diarrhea, and vomiting concentrated during dose escalation and mostly mild-to-moderate.

The higher-dose Phase 3 (GLORY-2) tested mazdutide 9 mg over 60 weeks in Chinese adults with BMI ≥30 kg/m² and reported topline results in October 2025: mean weight reduction of 20.08% in the non-diabetic subgroup versus 2.81% on placebo, with 48.7% of mazdutide participants achieving ≥20% loss compared with 3.1% on placebo (Innovent GLORY-2 topline release, October 2025). Innovent submitted the 9 mg supplementary application to the NMPA shortly after readout. The Phase 3 type 2 diabetes program — DREAMS-1 (mazdutide monotherapy versus placebo, n=320) and DREAMS-2 (mazdutide versus dulaglutide 1.5 mg, n=731) — read out in 2024–2025 with both trials meeting their HbA1c primaries and supporting the September 2025 NMPA approval for the T2D indication. DREAMS-1 was published back-to-back with the placebo-controlled Phase 3 in Nature in late 2025 (Zhu et al., Nature 2026, 652(8108):174–180).

The supporting evidence base is robust at the Phase 1b / Phase 2 layer. The Phase 1b multiple-ascending-dose trial of mazdutide 9 mg and 10 mg in Chinese adults with overweight or obesity was published in eClinicalMedicine (Ji et al., eClinicalMedicine 2022, 54:101691) and established the higher-dose tolerability profile. The Phase 2 obesity trial randomized 248 adults to 3 mg, 4.5 mg, 6 mg, or placebo for 24 weeks and reported placebo-adjusted body-weight reductions ranging from −7.7% to −12.3% across active arms (Ji et al., Nat Commun 2023, 14:8289). The Phase 2 T2D trial randomized 250 adults across mazdutide 3 / 4.5 / 6 mg, open-label dulaglutide 1.5 mg, and placebo for 20 weeks and reported HbA1c reductions of −1.41% to −1.67% on mazdutide versus −1.35% on dulaglutide (Chen et al., Diabetes Care 2024, 47(1):160–168). The Phase 2 → Phase 3 translation has been more consistent for mazdutide than for several other dual-agonist programs.

Three honest framings shape how the molecule should be read on this site. The first is the China-pathway question. The NMPA route is shorter than FDA review for the incretin class, and the Phase 3 evidence base supporting mazdutide is entirely Chinese — every trial in the GLORY and DREAMS programs enrolled Chinese participants at Chinese sites. East Asian populations have higher BMI-adjusted visceral-fat distribution and develop type 2 diabetes at lower BMI than Western populations, which is part of the rationale for studying the molecule in this population but also means the cross-population generalizability of the GLORY-1 and DREAMS readouts is genuinely uncertain. Whether the 14.8% weight-loss magnitude at the 6 mg dose, the 20.1% magnitude at the 9 mg dose, and the 80% relative liver-fat reduction translate quantitatively to non-East-Asian populations is an open empirical question. Lilly's decision to prioritize retatrutide over mazdutide for global development means this question is unlikely to be answered by a registrational Phase 3 in the foreseeable future.

The second is the dual-agonist class positioning. Mazdutide, survodutide, and pemvidutide are the three GLP-1 / glucagon dual agonists with active Phase 3 programs. Their receptor-affinity profiles differ — mazdutide leans modestly toward glucagon-receptor preference, survodutide is comparatively more GLP-1-biased, and pemvidutide sits between them. The clinical consequences of those affinity differences are not yet resolved at the head-to-head level; no published trial has compared any two of these molecules directly. The hepatic-fat signal from GLORY-1 invites the hypothesis that the glucagon-receptor component is doing meaningful work in liver-lipid reduction, but the hepatic fat decision guide is the place to read the comparative MASH pharmacology question carefully — the cross-trial design and population differences mean magnitude comparison should be hedged.

The third is the access landscape. Mazdutide is dispensed through licensed Chinese pharmacies as Xinermei; it is not available through any FDA-approved pathway in the United States, EU, or other Western jurisdictions. A gray-market access pattern has emerged consisting of direct-to-consumer importation from Chinese manufacturers and compounded products labeled "mazdutide" sourced through research-chemical channels. The site declines to grade specific suppliers or recommend access pathways; the relevant editorial observation is that mazdutide is a structurally complex 4,563-Da peptide with fatty-acid conjugation chemistry comparable in difficulty to semaglutide and tirzepatide, so the meaningful-purity supply question for compounded or gray-market product applies with the same force as for the rest of the class. The credibility of the GLORY and DREAMS trial results does not transfer to non-Innovent-manufactured supply.